🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Taiwan / NCT07151963
Enrolling by invitation Not applicable

Effects of Prolonged Continuous Theta Burst Stimulation in Chemotherapy-induced Peripheral Neuropathy

NCT07151963 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2025-02-17
Last updated
2025-09-11

Condition(s) studied

Breast Cancer Females

Investigational drug(s) / intervention(s)

prolonged continuous TBS20 Hz rTMS

prolonged continuous TBS: prolonged continuous theta burst stimulation

20 Hz rTMS: 20 Hz repetitive transcranial magnetic stimulation

Study summary

Laboratory studies have shown that prolonged continuous theta burst stimulation (pcTBS) provides better pain relief than 10 Hz repetitive transcranial magnetic stimulation (rTMS), with a shorter stimulation time, making it more practical for clinical use. Chemotherapy-induced peripheral neuropathy often causes neuropathic pain in cancer patients. The aims of this study are:

1. To compare the effects of pcTBS and 20 Hz rTMS on chemotherapy-induced peripheral neuropathy;
2. To compare the effects of pcTBS applied to the primary motor cortex versus the dorsolateral prefrontal cortex on neuropathic pain as well as depression and anxiety.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * breast cancer patients aged between 18- and 80-years-old with CIPN * history of receiving chemotherapy including taxane-based neurotoxic agents * with neuropathic pain, score≥3 in a 0-10 VAS pain scale. * with fair cognition and can cooperate to evaluate pain severity. * neither at end-stage cancer nor at the estimated survival time less than 6 months. Exclusion Criteria: * brain tumor or history of epilepsy * intracranial metallic devices, artificial cochleae, pacemakers, or any other metal device * recent myocardial ischemia or unstable angina * severe cognitive dysfunction or pregnancy * injuries or fractures in the part of neuropathic pain

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Taipei Tzu Chi Hospital New Taipei City Taiwan

More Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation trials in Taiwan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07151963 on ClinicalTrials.gov ↗ ← All trials in Taiwan